Naringin
description1
description2
Basic information
Product Name: Naringin
CAS No.: 10236-47-2
Molecular Formula: C₂₇H₃₂O₁₄
Physicochemical Properties:
Parameter |
Value/Description |
Appearance |
White to pale yellow crystalline powder |
Melting point |
171-174°C |
Solubility |
Poor in water (0.1 mg/mL), soluble in DMSO/methanol |
[α]D²⁰ |
-82° (c=1, ethanol) |
pKa |
7.2 (phenolic hydroxyl) |
Quality Standard: CP2020,JP,Customer Made
Specification
Test Items |
Standard |
Naringin (CAS: 10236-47-2) |
98% by HPLC |
Loss on drying |
≤5.0% |
Ash |
≤1.0% |
Abundant source
Pleiotropic effects
Prodrug characteristic
1.Molecular Target Network
2.Pharmacokinetics
Absorption
Hydrolyzed to aglycone in gut, bioavailability 5-8%
Distribution
92% plasma protein binding, low BBB penetration
Metabolism
Significant enterohepatic circulation, mainly UGT1A1/1A9 glucuronidation
Excretion
Primarily biliary (>60%), urinary <10%
Clinical Applications
Indication |
Mechanism |
Evidence Level |
Type 2 diabetes |
Glycosidase inhibition + insulin sensitization |
Phase II |
NAFLD |
Lipid metabolism + anti-fibrosis |
Animal models |
Chemoadjuvant |
Cisplatin nephrotoxicity mitigation |
Phase I |
Diabetes
Antioxidant
MTD
Safety Evaluation
1. Adverse Effects
System |
Incidence |
Manifestations |
Gastrointestinal |
15% |
Bloating, diarrhea |
Neurological |
3% |
Mild headache |
Hypersensitivity |
<1% |
Rash |
2. Drug Interactions
CYP3A4 substrates (e.g., statins): AUC may increase 2-3×
P-gp inhibitors (e.g., cyclosporine): Bioavailability ↑40%
Research Progress Green max
Novel Formulations
Phospholipid complex: Bioavailability →25%
Nanocrystals: 8× higher BBB penetration
Sustained-release microspheres: t₁/₂→12h
New Indications
Alzheimer's: 60% higher Aβ clearance (animal)
COVID-19: 3CL protease inhibition (IC₅₀=32 μM)
Please Send me email and you can get more what you want.
Such as product of Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.
Our experts will solve them in no time.